Sponsored Links
| Anacor Pharmaceuticals Announces First Patient Dosed In A Phase 2b Trial Of AN2728 For Psoriasis |
 |
 |
 |
| Medical News - Eczema and Psoriasis | |
|
Anacor Pharmaceuticals (NASDAQ:ANAC) announced that the first patient has been dosed in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide... Read more: Eczema / Psoriasis News From Medical News Today
|